Validation of Bulk Pharmaceutical Chemicals

Daniel Harpaz
Ira R. Berry

Interpharm Press, Inc.
Buffalo Grove, Illinois
CONTENTS

DEDICATION xiv

PREFACE xv

1. INTRODUCTION 1

Daniel Harpaz
Ira R. Berry

GMP Concepts 3
Regulatory 3
FDA Site Inspections 4
References 8
2. THE LEGAL FRAMEWORK FOR THE REGULATION OF BULK PHARMACEUTICAL CHEMICALS

David F. Weeda
Arthur Y. Tsien
Neil F. O’Flaherty

The Regulatory Status of BPCs
BPCs as “Drugs” 12
What Substances are BPCs? 13
BPCs as “New Drugs” or “New Animal Drugs” 14

BPC Adulteration
CGMP Noncompliance 16
Validation as Part of cGMPs 18
Other Forms of Adulteration 20

BPC Misbranding 22

BPC Inspections
History of BPC Inspections 23
Reasonable Inspections Under Section 374(a) 25
Scope of FDA Inspectional Authority over BPCs 27
Inspection Priorities: Active Drug Substances Versus Excipients 29
Foreign Versus Domestic Plant Inspection 30
Other Inspection Issues 31

Enforcement Tools Against BPCs
Administrative Tools 33
Judicial Tools 36
FDA Import/Export Authority over BPCs 40

Drug Master Files for BPCs
DMF Types 46
DMF Holder Obligations 47
Status of DMFs as Records 49

Conclusion 49
Notes 51
References 56
3. THE LEGAL BASIS FOR VALIDATION

Irving L. Wiesen

Current Good Manufacturing Practices 60
The 1962 Food and Drug Amendments 61
Challenges to the cGMPs 64
FDA’s Analysis of cGMPs 65
Judicial Analysis of cGMPs 66
“Open-Endedness” of the cGMP Framework 70
Failure to Comply With cGMPs Constitutes Product Adulteration 72

Bulk Pharmaceutical Chemical Standards 74
Validation 75
FDA’s Validation Guideline of 1987 77
Validation of Bulk Pharmaceuticals 79
The Barr Laboratories Decision 79

Conclusion 86
Notes 87
References 92

4. DRUG MASTER FILES

Arthur B. Shaw

Regulatory Basis for DMFs 94
Guideline 94
Relationship Between Holder and Applicant 95
Filing and Referencing a DMF 96
Review of a DMF 96
Approval of DMFs 101
Types of DMFs 101
Manufacturing Performed at More Than One Site 103
Intermediates 105
vi Contents

Rereview of DMFs for BPCs 105
Changing the Manufacturing Procedure in a DMF 109
Summary 110

5. BPC TERMINOLOGY AND DOCUMENTATION 111

Robert A. Nash

Active Drug Substance 115
Compendial Standards 118
Chiral BPCs 120
Premanufacturing Notice 121
The Validation of BPCs 123
Process Validation Options 123
Process Description 124
Impurity Profile 130
Retrospective Validation 130
Revalidation 131
Change Control 131
Reprocessing 132
Validation Master Plan 132
Cleaning Validation 133
Explosion Suppression Validation 136
Validation Documentation 137
Recommended Reading 140
References 141

6. BPC PROCESS VALIDATION: A CASE STUDY 143

Nirmal Khanna

Manufacturing Operations 144
Quality Assurance Systems 145
<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Validation Approach</td>
<td>146</td>
</tr>
<tr>
<td>Implementation of Validation Program</td>
<td>147</td>
</tr>
<tr>
<td>Retrospective Validation</td>
<td>147</td>
</tr>
<tr>
<td>Master Plan</td>
<td>147</td>
</tr>
<tr>
<td>Retrospective Validation Effort</td>
<td>150</td>
</tr>
<tr>
<td>Prospective Validation</td>
<td>152</td>
</tr>
<tr>
<td>Master Plan</td>
<td>155</td>
</tr>
<tr>
<td>Prospective Validation Effort</td>
<td>157</td>
</tr>
<tr>
<td>Prospective Protocols</td>
<td>158</td>
</tr>
<tr>
<td>Summary Report</td>
<td>158</td>
</tr>
<tr>
<td>Cleaning Operations</td>
<td>158</td>
</tr>
<tr>
<td>Cleaning Validation</td>
<td>162</td>
</tr>
<tr>
<td>Computer Control Systems Validations</td>
<td>164</td>
</tr>
<tr>
<td>Executive Summary</td>
<td>165</td>
</tr>
<tr>
<td>Validation File</td>
<td>165</td>
</tr>
<tr>
<td>Maintaining a “Validation State”</td>
<td>165</td>
</tr>
<tr>
<td>Conclusions</td>
<td>166</td>
</tr>
<tr>
<td>References</td>
<td>168</td>
</tr>
<tr>
<td>Acknowledgments</td>
<td>168</td>
</tr>
<tr>
<td>Appendices</td>
<td>169</td>
</tr>
<tr>
<td>1—SOPs at Ideal Corp.</td>
<td>169</td>
</tr>
<tr>
<td>2—Batch Records—A Validation Viewpoint</td>
<td>172</td>
</tr>
<tr>
<td>3—Outline of a Typical Retrospective Protocol</td>
<td>173</td>
</tr>
<tr>
<td>4—Outline of a Typical Prospective Protocol</td>
<td>175</td>
</tr>
<tr>
<td>5A—Miscellaneous IQ/OQ Activities</td>
<td>176</td>
</tr>
<tr>
<td>5B—Process Equipment</td>
<td>179</td>
</tr>
<tr>
<td>5C—Computer System Validation</td>
<td>182</td>
</tr>
<tr>
<td>6—Key Instruments Used in OQ Activities</td>
<td>183</td>
</tr>
<tr>
<td>7A—Retrospective Example</td>
<td>184</td>
</tr>
<tr>
<td>7B—Prospective Validation Protocol—Controlled Environment Example</td>
<td>193</td>
</tr>
<tr>
<td>7C—Prospective Validation Protocol—Supreme Process</td>
<td>202</td>
</tr>
<tr>
<td>7D—Prospective Validation Protocol—Cleaning Validation</td>
<td>210</td>
</tr>
<tr>
<td>7E—Prospective Validation Protocol—Micropulverization of Supreme</td>
<td>220</td>
</tr>
</tbody>
</table>
7. BULK PHARMACEUTICAL CHEMICAL VALIDATION: AN OVERVIEW AND COMPARATIVE ANALYSIS 233

Max S. Lazar

FDA Focus 234
Industry Reaction 234
Validation: A Comparison of Dosage Form Versus Bulk Pharmaceutical Chemicals 235
Development Report 237
Technology Transfer 238
Change Control 239
Defined Critical Steps 240
Well-Defined Purification 240
Types of Validation 241
   Retrospective Validation 241
   Prospective Validation 242
   Concurrent Validation 242
The Future Horizon 243
References 243

8. VALIDATION OF STERILE BULK PHARMACEUTICAL CHEMICALS 245

Robert V. Kasubick

Regulatory Aspects 247
Validation Protocol Format 248
General Manufacturing Process Description 248
Facility 250
   Room Classification 250
   Airflow Patterns and Pressure Differentials 252
   Personnel Flow 255
   Material Flow 256
Support Systems
  Water Systems  257
  Air Systems  260
  Equipment Sterilization  261
  Clean Steam System  263
  Filtration Systems  263
  Heat Exchangers  265
  Vacuum Systems  265

Manufacturing Process Validation  266
Validation Maintenance  268
References  269

9. VALIDATION OF BIOTECHNOLOGY
   BULK PHARMACEUTICALS  271

Rob Murphy
Robert J. Seely

Master Planning  272

Equipment Qualification  273
  Installation Qualification  274
  Operational Qualification  275
  Performance Qualification  275

Cleaning Validation  275
Equipment Sterilization  278
Process Validation  278
  Timing  280
    Process Variables  282
    Additional Studies  287
    The Final Package  288
    Ongoing Validation  289
    Change Control  290
    Revalidation  293

References  295

Appendix: Process Validation Protocol PV-08  296
10. QUALITY ASSURANCE SYSTEMS 301

Fred C. Radford

Definition and Decision 308
FDA Requirements Are Central 315
The Inspection Focus 317
Manufacturing Instructions and Beyond 319
Tangent Considerations 322
Plan, Do, Study, Act 325
References 333

11. CLEANING FOR BULK PHARMACEUTICAL CHEMICALS (BPCs) 335

William E. Hall

Regulatory Requirements 336
Multiple Use Versus Dedicated Equipment 337
The Unique Nature of BPCs 338
Multiple Levels of Cleaning 339
  Level 1 Cleaning 340
  Level 2 Cleaning 340
  Level 3 Cleaning 341
  Level 4 Cleaning 341
  Philosophy of Cleaning 341
Nature of Contaminants 342
Product Groupings and Worst-Case Selection 344
Cleaning Techniques 345
Sampling 346
Analytical Methods 348
  Visual Examination 351
  Analytical Techniques for Biotechnology Cleaning Validation 352
  High Performance Liquid Chromatography 352
12. VENDOR QUALIFICATION AND CERTIFICATION 371

Ira R. Berry

Definition of Terms 372
Purpose of Vendor Qualification and Certification 374
Qualification/Certification Procedure Overview 375
How to Qualify a Vendor 376
Certifying a Vendor 381
Monitoring a Vendor 382
Vendor Audits
   Philosophy of Pharmaceutical GMP Compliance 385
   Documentation 385
   Quality Control/Quality Assurance Program 386
   Standard Operating Procedures Manual 386
   Change Control Procedure 386
   Personnel Training 387
   Out-of-Specification Data Handling/Failure Investigation 388
   Written Master Production and Control Records with In-Process Controls 388
   Rework Procedure 388
   Process Validation Program 389
   Cleaning Validation 389
Contents

Analytical Methods Validation  389
Stability Program  389
Control of Suppliers  390
Distribution Records  390
Recall Procedure and Capability  391
Product Complaint Handling Procedure  391
Returned Goods Procedure  391
Safety Program  392
Current Drug Master File  392
Internal/External Audit Program  392
Calibration Program  393
Facilities and Equipment Preventive Maintenance Program  394
Materials and Labeling Control  394
The Auditors  395
Be Prepared  396
Some Common Plant Issues  396
Preparation Aids  399
References  400

13. MICROBIOLOGICAL ATTRIBUTES OF BULK PHARMACEUTICAL CHEMICALS  403

Karen Zink McCullough
John T. Shirtz

Microbiological Quality of Water  407
Validation and Maintenance of the Water System  410

Bioburden  411
BPC Processing  414

Facility Considerations for the Production of Sterile BPCs  416

Monitoring the Environment in BPC Manufacturing Facilities  421
Microbiological Monitoring of Air  421
Microbiological Monitoring of Surfaces  424
Microbiological Monitoring of Operators  425
Use of Isolator Systems to Minimize Human Contact With Sterile BPCs
   Containment  426

Microbiological Testing of Finished Sterile BPCs
   Sterility Testing  428
   Testing of BPCs for the Presence of Pyrogens  429
   Endotoxin Limits  432

Summary  437
Glossary  438
References  442

14. EXCIPIENTS: FACILITY, EQUIPMENT, AND PROCESSING CHANGES  447

   Irwin Silverstein

   Identification of Significant Process Change  453
   Facility  460
   Equipment  461
   Processing  464
   Conclusion  468
   References  469

INDEXES

   Name Index  471
   Subject Index  475